BioDlink’s Bevacizumab Receives Market Approval in Indonesia

BioDlink’s Bevacizumab Injection has officially received approval from Indonesia’s National Agency of Drug and Food Control (BPOM), adding to its previous approvals in Nigeria, Pakistan, and Colombia. This achievement accelerates the global commercialization efforts of BioDlink. The approval in Indonesia, the largest pharmaceutical market in ASEAN, bolsters BioDlink’s position as a leading supplier of antibody and XDC therapies, meeting international GMP standards and showcasing strong commercial capabilities. The announcement was made by BioDlink on August 21, 2025, signaling a successful expansion into emerging markets over the past two months.